Arthritis Market
Arthritis Market

Arthritis Market Analysis 2019 to 2026 With Key Players F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Eli Lilly and Company, Novartis AG, Sanofi

Global Arthritis Market By Rheumatoid Drug Type (Biologics, Non-Biologics, Steroids, Analgesics, Glucocorticoids, Others), Rheumatoid Diagnosis (CRP Test, CCP, ESR Test), Rheumatoid Treatment (Synovectomy, Tendon Repair, Joint Fusion, Symptomatic Treatment, Intermediate Corticosteroid Therapies, DMARD Therapies), Osteoarthritis Type (Hip, Spinal, Knee, Foot & Ankle, Shoulder, Hand), Osteoarthritis Diagnosis (Imaging, Joint Fluid Analysis, Others), Osteoarthritis Treatment (Medication, Drugs, Assistive Devices, Surgery, Therapy), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Drug Stores), End-Users (Hospitals, Clinics, Household, Medical Institutes, Research Organizations, Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) – Industry Trends and Forecast to 2026

Global Arthritis Market is expected to register a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the increasing awareness regarding the disease and the modes of its treatment.

Get Sample Report @

Some of the major competitors currently working in the global arthritis market are AbbVie Inc.; Pfizer Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; CELGENE CORPORATION; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; UCB S.A.; Gilead Sciences, Inc.; Eli Lilly and Company; Novartis AG; Sanofi; AstraZeneca; Astellas Pharma Inc.; Galapagos NV; Taisho Pharmaceutical Holdings Co., Ltd.; Boehringer Ingelheim GmbH; Swedish Orphan Biovitrum AB (publ); Regeneron Pharmaceuticals; Abiogen Pharma Spa; Merck & Co., Inc.; Kolon TissueGene, Inc.; Ampio Pharmaceuticals Inc.; GlaxoSmithKline plc among others.

Market Definition: 

Arthritis, also known as inflammation of joints is described as the tenderness or swelling occurring in the joints of patients, with the symptoms of the disease being stiffness and pain in joints. It is categorized into two most common variants as rheumatoid arthritis and osteoarthritis. The patient suffers from significant lack of motion

Market Drivers

  • Rising cases of rheumatoid arthritis  worldwide will accelerate the market growth
  • Increasing aging population is another factor uplifting the market growth
  • Growing demand for minimally invasive procedures among population will also enhance the market growth
  • Increasing obesity among population also acts as market driver in the forecast period

Market Restraints

  • Increasing risk of side effects associated with treatment of arthritis will restrain the market growth
  • High cost of hyaluronic acid products will hinder the growth of the market
  • Lack of effective treatment other than symptomatic mode for osteoarthritis also acts as a market restraint

Table of Content: Global Arthritis Market

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Global Arthritis Market Landscape

Part 04: Global Arthritis Market Sizing

Part 05: Global Arthritis Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

And More…..Get Detailed TOC @

Segmentation: Global Arthritis Market

By Rheumatoid Drug Type

  • Biologics
    • TNF- α Antagonists
    • T-Cell Inhibitors
    • CD20 Antigen
    • JAK Inhibitors
    • Anti-IL6 Biologics
  • Non-Biologics
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
    • Synthetic Disease-Modifying Antirheumatic Drugs (SDMARDs)
  • Steroids
  • Analgesics
  • Glucocorticoids
  • Others

By Rheumatoid Diagnosis

  • C-Reactive Protein (CRP) Test
  • Cyclic Citrullinated Peptide (CCP)
  • Erythrocyte Sedimentation Rate (ESR) Test

By Rheumatoid Treatment

  • Synovectomy
  • Tendon Repair
  • Joint Fusion
  • Symptomatic Treatment
  • Intermediate Corticosteroid Therapies
  • Disease-Modifying Anti-Rheumatic Drug (DMARD) Therapies
    • Conventional Disease-Modifying Anti-Rheumatic Drug (DMARD)
    • Biologic Disease-Modifying Anti-Rheumatic Drug (DMARD)

By Osteoarthritis Type

  • Hip
  • Spinal
  • Knee
  • Foot & Ankle
  • Shoulder
  • Hand

By Osteoarthritis Diagnosis

  • Imaging
    • X-Rays
    • Magnetic Resonance Imaging (MRI)
    • Others
  • Joint Fluid Analysis
  • Others

By Osteoarthritis Treatment

  • Medication
    • Analgesics
      • Acetaminophen
      • Duloxetine
      • Others
    • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
      • Aspirin
      • Ibuprofen
      • Naproxen Sodium
      • Naproxen
      • Others
    • Others
  • Drugs
    • Food Supplements
      • Corticosteroids
      • Hyaluronic Acid Injection
        • Single Injections
        • Multiple Injections
      • Phase III Drugs
      • Others
  • Assistive Devices
  • Surgery
  • Therapy
    • Non-Pharmacological Therapy
    • Pharmacological Therapy

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Drug Stores

By End-Users

  • Hospitals
  • Clinics
  • Household
  • Medical Institutes
  • Research Organizations
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Developments in the Market:

  • In October 2019, Gilead Sciences, Inc. announced that they had submitted a new drug application (NDA) for their investigational, oral, selective JAK 1 inhibitor, “filgotinib” for treatment of adults suffering from rheumatoid arthritis to the Japanese Ministry of Health, Labour and Welfare (MHLW). This application will enable the company to enhance their presence in the region for providing therapeutics for inflammation
  • In August 2019, AbbVie announced that they had received U.S. FDA approval for “RINVIQ (upadacitinib)”, once-daily 15 mg oral Janus Kinase (JAK) inhibitor designed for the treatment of adults suffering from moderate to severe range of rheumatoid arthritis having an inadequate response to methotrexate (MTX-IR). The drug will be available from late August, 2019

Competitive Analysis:

Global arthritis market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of arthritis market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

  • Current and future of global arthritis market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Order a Copy of This Research Report @

About Data Bridge Market Research 13858 Articles
Hi, I am Ravi Kumar, a Blogger, Freelancer, SEO Consultant, an Internet Marketer, I am a research analyst who loves to evaluate data relating to Manufacturing industry, Management of companies and enterprises, Finance and insurance, Wholesale trade, Management, scientific, and technical consulting services

Leave a Reply

Your email address will not be published.